Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|August 28, 2013

Amarin Targets Novasep as Fourth Supplier of Vascepa API

Amarin released the submission of an sNDA to FDA seeking approval for Novasep Group.

Amarin, a biopharmaceutical company, has filed a supplemental new drug application with FDA seeking approval to make Novasep Group, through its subsidiary Finorga, as an additional supplier of icosapent ethyl, the API in Vaseepa Amarin’s omega-3-fatty acid product supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.

Novasep, a provider of purification technologies and API manufacturing, is building a chromatography plant using its proprietary chromatography technologies to produce API on behalf of the Slanmhor consortium and Amarin. Amarin anticipates the Novasep facility, located in Mourenx, France, to be qualified and operational for manufacturing in 2014.

Source: Amarin


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.